Testing a virus called M032 in children and adults with newly diagnosed diffuse midline glioma
Original title: Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether a lab made virus, put right into the tumor, is safe for people with this brain tumor after they finish radiation.
Who this trial is for. This trial is for children and adults with a brain tumor called diffuse midline glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, or DMG, that was found recently. It is testing M032, a changed form of the herpes simplex virus, given straight into the tumor after the person has had standard radiation.
Where it stands. There are no results to share yet. The trial team is looking at how safe M032 is and what effects it has. That answer is not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: For now this is a study, not care your own doctor can give you. If this sounds like your situation, you can ask your care team about it. They can help you think through whether a trial makes sense for you.
What it doesn't mean: This does not mean M032 works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that it will help you, and it is not a promise of a cure. The main goal here is to learn whether this is safe.
Source: ClinicalTrials.gov, July 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.